Mezigdomide

Summary

Mezigdomide (CHEMBL4648616) is a phase-3 clinical-stage small molecule targeting CRBN; indicated across 3 conditions including plasma cell myeloma and liver disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (CRBN)
• Indications: 3 conditions
• Clinical trials: 26
• Chemistry: 567.6 Da · C32H30FN5O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4648616
Name	Mezigdomide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	137379043
Molecular formula	C32H30FN5O4
Molecular weight	567.6
InChIKey	YTINZZFBHWSAGL-NDEPHWFRSA-N

SMILES: C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCN(CC5)C6=C(C=C(C=C6)C#N)F

IUPAC name: 4-[4-[[4-[[2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-3H-isoindol-4-yl]oxymethyl]phenyl]methyl]piperazin-1-yl]-3-fluorobenzonitrile

Also known as: Cc-92480, CC-92480, CC92480, Mezigdomide, MEZIGDOMIDE, MEZIGDOMIDE (CC-92480), CPD. 3(CC-92480)

Patent coverage: 156 distinct patent families (477 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 347 (73%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CRBN	cereblon	Binding	7.52	0.2%	Q96SW2

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Protein cereblon/DNA damage-binding protein 1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DDB1	7.52	IC50	30	nM	CHEMBL_ACT_20707776

Target pathways

Aggregated over 1 target gene(s): CRBN.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
Potential therapeutics for SARS	1	CRBN

Dominant GO biological processes

GO term	Targets
protein ubiquitination	1
positive regulation of Wnt signaling pathway	1
negative regulation of protein-containing complex assembly	1
positive regulation of protein-containing complex assembly	1
negative regulation of monoatomic ion transmembrane transport	1
locomotory exploration behavior	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
limb development	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
liver disorder	1	MONDO:0005154	EFO:0001421
kidney disorder	1	MONDO:0005240	EFO:0003086

Clinical trials

Total trials: 26.

Phase distribution

Phase	Trials
PHASE1	14
PHASE1/PHASE2	8
PHASE3	2
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05519085	PHASE3	RECRUITING	A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05552976	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT02343042	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT03989414	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
NCT05372354	PHASE1/PHASE2	RECRUITING	A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT06627751	PHASE2	RECRUITING	Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
NCT06645678	PHASE1/PHASE2	RECRUITING	Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
NCT06988488	PHASE1/PHASE2	RECRUITING	A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT07356154	PHASE1/PHASE2	RECRUITING	A Study of Revumenib and Mezigdomide in People With Leukemia
NCT03374085	PHASE1/PHASE2	TERMINATED	A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
NCT06050512	PHASE1/PHASE2	WITHDRAWN	Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
NCT05651932	PHASE1	RECRUITING	A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
NCT05981209	PHASE1	ACTIVE_NOT_RECRUITING	Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
NCT06048250	PHASE1	RECRUITING	Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
NCT06121843	PHASE1	RECRUITING	A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT07032714	PHASE1	RECRUITING	Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
NCT07105059	PHASE1	RECRUITING	A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
NCT07355335	PHASE1	NOT_YET_RECRUITING	Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
NCT03803644	PHASE1	COMPLETED	Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects
NCT04211545	PHASE1	COMPLETED	Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects
NCT04839809	PHASE1	COMPLETED	A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants
NCT05389722	PHASE1	COMPLETED	A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants
NCT05707390	PHASE1	COMPLETED	A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
NCT06163898	PHASE1	TERMINATED	A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06318676	PHASE1	COMPLETED	A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
NCT06994117	Not specified	AVAILABLE	Expanded Access for Mezigdomide

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

18 molecules share ≥1 primary target. Top 18 by shared-target count:

Molecule	Source	Status	Shared targets
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	CRBN
POMALIDOMIDE	ChEMBL + PubChem	Phase 4 (approved)	CRBN
ASCIMINIB	ChEMBL	Phase 4 (approved)	CRBN
BRIGATINIB	ChEMBL	Phase 4 (approved)	CRBN
DASABUVIR	ChEMBL	Phase 4 (approved)	CRBN
LENALIDOMIDE	ChEMBL	Phase 4 (approved)	CRBN
PONATINIB	ChEMBL	Phase 4 (approved)	CRBN
THALIDOMIDE	ChEMBL	Phase 4 (approved)	CRBN
IBERDOMIDE	ChEMBL	Phase 3	CRBN
URACIL	ChEMBL	Phase 3	CRBN
VEPDEGESTRANT	ChEMBL	Phase 3	CRBN
ADAVOSERTIB	ChEMBL	Phase 2	CRBN
AVADOMIDE	ChEMBL	Phase 2	CRBN
E-7820	ChEMBL	Phase 2	CRBN
FORETINIB	ChEMBL	Phase 2	CRBN
INDISULAM	ChEMBL	Phase 2	CRBN
Fulvestrant	PubChem	Approved	CRBN
Sotorasib	PubChem	Approved	CRBN